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Symptoms of atopic asthma often disappear at puberty. However,
asthmatic subjects in clinical remission will frequently have a re-
lapse later in life. The aim of this study was to investigate whether
subjects in clinical remission of atopic asthma have persistent air-
way inflammation and/or airway remodeling. Bronchial biopsies
were obtained from subjects in clinical remission, asthmatic sub-
jects, and healthy control subjects. The presence and/or activation
state of eosinophils, mast cells, macrophages, T lymphocytes, in-
terleukin (IL)-5, eotaxin, and inducible nitric oxide synthase (iNOS)
were analyzed. Results were compared with less invasive indica-
tors of airway inflammation. Also aspects of airway remodeling
were determined. Eosinophils, T cells, mast cells, and IL-5 were
significantly elevated in the airway mucosa of subjects in remission
compared with control subjects. Also, blood eosinophil cell counts
were significantly higher in subjects in clinical remission. Blood
eosinophil cell counts, exhaled nitric oxide (eNO) levels, and bron-





cantly with the quantity of tissue eosinophils. Significant airway
remodeling was found in subjects in clinical remission. Our study
has shown ongoing airway inflammation and airway remodeling
in adolescents in clinical remission of atopic asthma. Subclinical
airway inflammation may well determine the risk of an asthma re-
lapse later in life.
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Symptoms of atopic asthma often begin in early childhood and
mostly improve or even seem to disappear at puberty (1, 2).
However, a considerable proportion of asthmatic subjects in
clinical remission will have a relapse later in life (1). Several
studies have shown spirometric abnormalities and bronchial
hyperresponsiveness (BHR) to methacholine (MCh) or cold
air challenge during clinical remission of asthma (3, 4). It is
unknown whether these functional abnormalities, which are
supposed to be indicative of asthma severity with respect to
symptomatic asthma, reflect persistent activity of the airways
inflammatory process or merely indicate structural changes of
the airways as a consequence of childhood asthma. These
structural changes, known as airway remodeling, are probably
early events in the course of the disease that appear to progress.
The process of remodeling leads to thickening of the airway
wall (5–7). The exact physiologic consequences of airway wall
thickening are, however, incompletely understood (8). If air-
way wall thickening is present in subjects in clinical remission
of asthma, it could at least in part account for the functional
abnormalities including bronchial hyperresponsiveness, found
during remission. On the other hand, ongoing active airway
inflammation could have substantial impact on the risk of a re-
lapse later in life. As a consequence, subjects with subclinical
airway inflammation could benefit from anti-inflammatory
treatment (8–10). Recently, we demonstrated elevated ex-





-monophosphate (AMP) during clinical remission
of atopic asthma (11). With respect to eNO, increased expres-
sion of the inducible form of nitric oxide synthase (iNOS) is
thought to underlie these elevated eNO levels (12, 13). Studies
regarding the precise relationship between iNOS expression
and eNO are, however, scarce (12).
Proof of persistent airway inflammation and remodeling
during clinical remission could be furnished from the analysis
of bronchial biopsy specimens. Evidence has been accumu-
lated to suggest that allergen-reactive type 2 T helper (Th2)
cells, with eosinophils and mast cells as main effector cells, or-
chestrate asthmatic airway inflammation (14, 15). The pres-
ence of eosinophils in the airway wall is apparently the most
reliable feature of bronchial asthma that seems to be related
to asthma severity (16). Along with interleukin (IL)-5, a Th2
cytokine, and eotaxin, a chemoattractant for eosinophils, eosin-
ophil-derived products such as major basic protein (MBP)
have been investigated as markers of eosinophil participation
in the pathogenesis of asthma (17). Also, elevated numbers of
bronchial mast cells have been found in the airway mucosa
of atopic and nonatopic asthmatic subjects (18, 19). Release of
mediators from mast cells such as granule-associated tryptase
and chymase leads to immediate bronchoconstriction and en-
hances airway inflammation (19).
In healthy airways, the inflammatory response to such as
inhaled allergens is suppressed by alveolar macrophages. In
asthma, however, a deviant function of alveolar macrophages
may contribute to the allergic immune response in the airways
(20).
How numbers and activation state of these different cell
types in the bronchial mucosa relate to less invasive markers
of airway inflammation, including BHR, circulating eosino-
phils, and eNO, is largely unclear (21–23).
Remodeling of the airway mucosa and submucosa can be
assessed by measurement of the reticular basement mem-
brane (RBM) thickness (24) and extent of epithelial shedding
(25). Also, collagen deposition (26) is a quantifiable aspect of
airway remodeling.
To establish whether subjects in clinical remission of atopic
asthma suffer from ongoing active airway inflammation and/or
airway remodeling, we compared bronchial biopsy specimens
of subjects with a long-standing clinical remission of atopic
asthma with those of currently asthmatic subjects and of
healthy control subjects. Biopsy findings were compared with
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Adolescents 18 to 25 yr of age with atopic asthma were selected from
the Sophia Children’s Hospital discharged patients files. Clinical re-
mission of atopic asthma was defined as reported complete absence of
asthmatic symptoms in subjects not taking any asthma medication for
at least 12 mo prior to the study. Eligible subjects were compared with






-agonists on demand in order to relieve symptoms. Atopic asthma
was previously diagnosed in all subjects according to ATS criteria
(27). All subjects were lifelong nonsmokers in stable clinical condition
and did not take inhaled steroids or antiallergic medication. Healthy
nonsmoking adult volunteers without a history of asthma served as
controls.
The study was approved by the Medical Ethics Committee of the




We performed a cross-sectional study with three visits on separate
days. Spirometry values, eNO, MCh, and AMP responsiveness were




Venous blood eosinophil numbers were counted by means of hemocy-












An experienced bronchoscopist (SEO) using an Olympus model BF
IT 10 (Olympus, Tokyo, Japan) performed flexible bronchoscopy. At
least five bronchial biopsies were obtained from segmental divisions
of the main bronchi.
 
Processing of Bronchial Biopsies
 
Bronchial biopsies were embedded in Tissue-Tek II OCT medium












m) were cut on a HM-560 cryostat










croscopic slide (Sigma Diagnostics, St. Louis, MO). Immunostaining





















































Binding of the antibodies was detected by the immunoalkaline
phosphatase antialkaline phosphatase (APAAP) method. Immuno-
stained sections were analyzed with an image analysis system (Quan-
timed, Leica, Rijswijk, The Netherlands). With respect to the subepi-




m below the reticular
basement membrane (RBM). The ratio of positive stained area di-
vided by the total area analyzed was taken as measure for each immu-





m intervals over a 1-mm RBM length (24). The occupancy of
RBM with epithelium was plotted as ratio of occupied membrane









 SEM. Comparisons between groups were made by
the Mann-Whitney test for unpaired samples. Correlation between
different indices was made by Spearman’s rank correlation test. A
two-tailed p value of equal to or less than 0.05 was considered signifi-
cant. Data were analyzed using Statistical Package for the Social Sci-




Fifty-four subjects completed the study (19 subjects with
atopic asthma, 18 subjects in clinical remission of atopic
asthma, and 17 healthy control subjects). Subjects’ character-
istics are summarized in Table 1. The median duration of clin-
ical remission was 5 yr. Immunohistochemistry results are
summarized in Table 2.
In both epithelium and subepithelium of airway mucosa
specimens, MBP density was significantly greater in subjects










 0.001, respectively) (Figures 1 and 2). In bronchial epithe-
lium of subjects in remission, there was more tryptase present




 0.001). In subepi-
thelium, however, there was more tryptase detectable in sub-









 0.025, respectively) (Figures 3 and
4). Chymase density was greater in bronchial epithelium and
subepithelium of subjects in remission than in that of healthy

















 cells in both epithelium and subepithelium between





 cells present in the subepithelium of subjects in remis-




 0.04). No such




 cells were equally
represented in subepithelium and epithelium in all three ex-
perimental groups.
In subepithelium, IL-5 density was significantly greater in




0.006). Eotaxin density was significantly greater in patients





whereas intermediate levels were detected in subjects in re-
mission. In the epithelium, densities of IL-5 and eotaxin were
similar in all three groups. Density of iNOS was significantly
greater in subepithelium of healthy subjects than in that of




 0.05). In the epithelium, iNOS den-





 0.05). No difference in iNOS density could be detected
between healthy control subjects and subjects in clinical re-
mission.
With respect to indices of remodeling, RBM thickness dif-































). Furthermore, in subjects in remis-
sion the RBM occupancy with epithelium differed significantly






 0.003), and from values from current asthmatic










Collagen type III density in biopsy specimens was not signifi-
cantly different between the groups.
In peripheral blood, the number of eosinophils was signifi-
cantly elevated in subjects in remission when compared with






























 0.001) (Figure 6). Median eosinophil count


























































































































, expressed as increase in % of predicted normal value after admin-
istration of 1 mg terbutaline.
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In subjects in remission and those with asthma, a significant
positive correlation was found between blood eosinophil cell






















). A similar correlation was observed
for eNO values (11) and MBP density in bronchial epithelium


























 AMP values correlated inversely
with MBP density in subepithelium of subjects in remission and












 0.032). In contrast, no sig-





and MBP density in bronchial biopsy specimens. In subjects in re-






























In this study we demonstrated the presence of an ongoing active
inflammatory process in the airways during long-lasting clinical
remission of atopic asthma, as reflected by significantly increased
levels of MBP, tryptase, chymase, CD25, and IL-5 in bronchial
epithelium and/or subepithelium. In addition, eosinophil cell
counts in blood samples were significantly elevated during clini-
cal remission compared with those in healthy control subjects.
Less invasive indicators of airway inflammation such as blood




AMP showed a significant correla-
tion with MBP density in biopsy specimens from subjects in re-
mission and patients with asthma. We also found evidence of air-
way remodeling during clinical remission. There was a significant
correlation between RBM thickness and bronchial hyperrespon-
siveness to AMP.
Airway inflammation has been demonstrated in subjects
with symptomatic asthma (28, 29). However, studies regarding
the presence of inflammation in bronchial biopsy specimens
from prolonged symptom-free subjects with a history of atopic
asthma are lacking. Therefore, we applied a strict definition of
clinical remission, where subjects were regarded in clinical re-
mission if they reported complete absence of cough, chest dis-
comfort, or breathlessness for at least 1 yr preceding the study,
and did not use any medication in order to control asthma
symptoms. In our study population, the median duration of re-
mission was 5 yr with only one subject who had been in remis-
sion for just 1 yr. Not withstanding these strict inclusion crite-
ria, we are the first to show direct evidence of substantial
active airway inflammation, suggesting persistent disease in
these otherwise asymptomatic subjects.
Increased numbers of eosinophils, one of the most impor-
tant effector cells in atopic asthma, have been demonstrated in
the bronchial mucosa of patients with asthma (17). We present
similar findings in the bronchial mucosa of subjects in clinical
remission. Also, elevated levels of tryptase- and chymase, con-
stituents and markers of mast cells, were detected in the bron-
chial mucosa of subjects in remission compared with those of
healthy control subjects. On the other hand, we found reduced
tryptase density in the airway wall mucosa of subjects with
asthma as compared with subjects in remission. This is sugges-
tive of enhanced degranulation of mast cells in patients with
asthma compared with subjects in clinical remission. Upon de-
 


































































































 0.0050 0.0123 	 0.0032 0.0058 	 0.0039
CD69 0.0095 	 0.0116 0.0076 	 0.0182 0.0123 	 0.0093
CD68 0.029 	 0.0054 0.038 	 0.0067 0.031 	 0.019
IL-5 0.038 	 0.0097 0.036 	 0.018 0.017 	 0.014
Eotaxin 0.001 	 0.0013 0.0002 	 0.0045 0.0002 	 0.0005
INOS 0.12 	 0.02 0.15 	 0.03 0.21 	 0.03
Collagen III 0.078 	 0.011 0.077 	 0.024 0.062 	 0.009
Subepithelium
MBP 0.12 	 0.026† 0.07 	 0.024† 0.0042 	 0.0086
Tryptase 0.037 	 0.0082 0.075 	 0.012§ 0.022 	 0.010
Chymase 0.014 	 0.0038 0.018 	 0.0056‡ 0.0069 	 0.0033
CD4 0.0043 	 0.0040 0.0025 	 0.0019 0.0041 	 0.0027
CD8 0.022 	 0.0040 0.014 	 0.0033 0.019 	 0.004
CD25 0.0094 	 0.0126 0.0356 	 0.0233‡ 0.0095 	 0.0041
CD69 0.0062 	 0.0198 0.0156 	 0.0273 0.0085 	 0.0063
CD68 0.058 	 0.0069 0.069 	 0.013 0.079 	 0.032
IL-5 0.025 	 0.0061 0.022 	 0.0074§ 0.0066 	 0.0081
Eotaxin 0.0011 	 0.0006‡ 0.0001 	 0.0087 0.0001 	 0.0003
INOS 0.041 	 0.006 0.042 	 0.014‡ 0.065 	 0.016
Collagen III 0.16 	 0.014 0.19 	 0.016 0.17 	 0.019
* Variables are expressed as median density (ratio of positively stained area and total
area) 	 SEM.
† p  0.001 versus healthy control subjects.
‡ p  0.05 versus healthy control subjects.
§ p  0.01 versus healthy control subjects
 p  0.05 versus remission subjects.
Figure 1. Ratio of area of Major Basic Protein (MBP) staining and total
area of epithelium (top panel) and of subepithelium (bottom panel) in
bronchial biopsy specimens from currently asthmatic subjects, subjects
in clinical remission of atopic asthma, and healthy control subjects.
Each closed circle represents one subject. Horizontal bars represent
median values. Y-axis shows values logarithmically.
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granulation, mediators are diluted out into the tissue environ-
ment and rapidly degraded (30).
In the airway mucosa, there was no significant difference
between the groups with respect to the presence of T cells. In
previous studies, elevated T-cell numbers were found in the
airway mucosa, even in patients in whom asthma was newly num-
bers of T cells in bronchial mucosa specimens (32, 33), or just
an increase in activated T-cell numbers (34, 35). We found ele-
vated levels of CD25 expression in bronchial subepithelium of
subjects in remission compared with healthy subjects, which
was not demonstrated in patients with asthma. The number of
CD69 cells was not elevated. In our study, patients with
asthma were in stable phase of disease and by definition the
subjects in remission were without clinical symptoms all to-
gether. Therefore, disease activity should be regarded low in
both groups. This may explain the absence of significantly ele-
vated density of T-cells. However, we did find increased levels
of activated cells, albeit not with an early marker of activation.
We found similar CD68 levels in all three groups. This may
indicate that total macrophage numbers are relatively unim-
portant for asthma, and that a transformed and activated sub-
set of these cells may be responsible for disease activity (20).
The relationship between markers of inflammation in bron-
chial biopsy specimens and other indices that presumably re-
flect distinct aspects of the inflammatory process, including pe-
ripheral blood eosinophils, eNO and the degree of BHR to
various inhaled stimuli, is controversial. It has been proposed
that determination of numbers of eosinophils in peripheral
blood may help to indicate the level of airway inflammation
(21). In the present study, blood eosinophil numbers correlated
significantly with airway mucosal MBP density. Therefore,
blood eosinophil cell numbers might serve as an indicator of
eosinophilic airway inflammation in otherwise symptom-free
subjects with a history of atopic asthma.
A relationship between elevated cell numbers and/or cell
activity in bronchial biopsy specimens and BHR has been dem-
onstrated in some other studies (23, 36). Especially BHR with
AMP as the inhaled stimulus has been proposed as a useful
marker reflecting at least part of the inflammatory process in
asthma (37). We found a significant correlation between
PD20AMP and MBP density in the airway wall mucosa in pa-
tients with current asthma and subjects in clinical remission of
asthma. However, such a correlation could not be established
Figure 2. Bronchial biopsy specimen from a healthy control subject
(top panel) and a subject in clinical remission of atopic asthma (bottom
panel) immunostained with -Major Basic Protein (MBP). Notice the
increased MBP-positive area (the red stain) and epithelial shedding in
the subject in clinical remission.
Figure 3. Ratio of area of tryptase staining and total area of epithelium
(top panel ) and sub-epithelium (bottom panel) in bronchial biopsy
specimens from currently asthmatic subjects, subjects in clinical remis-
sion of atopic asthma, and healthy control subjects. Each closed circle
represents one subject. Horizontal bars represent median values. Y-axis
shows values logarithmically.
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between PD20MCh values and MBP density in the airway mu-
cosa. This is in agreement with other reports where MCh re-
sponsiveness appeared to be unrelated to indices of inflamma-
tion determined in bronchial biopsy specimens, and more to
structural changes of the airways (22, 38). Previously, we re-
ported that levels of eNO were significantly correlated with
PD20AMP, but not with PD20MCh (11). This is in agreement
with finding that both PD20AMP and eNO are related to the
activity of cells known to play a role in the inflammatory pro-
cess in asthma. In contrast, MCh acts directly on smooth mus-
cle (SM) cells in the airway walls. Therefore, the response to
MCh potentially reflects the structural changes found in
asthma (39). This is supported by the fact that bronchial hy-
perreactivity to MCh may exist independently of active airway
inflammation (40). The fact the MCh acts directly on SM cells
may explain the absence of a correlation between BHR to
MCh and RBM thickness. On the other hand, the positive cor-
relation between BHR to AMP and RBM thickness may be
explained by the presumed contribution of inflammatory me-
diators to the process of RBM remodeling.
Although epithelial desquamation may be an artifact of tis-
sue sampling and not a true pathologic feature of the disease
(41), we were able to demonstrate that the denudation of the
RBM is much more progressive in patients with asthma than
in subjects in remission. In subjects in remission, denudation is
Figure 4. Bronchial biopsy specimen (-tryptase) from a healthy con-
trol subject (top panel ) and a subject in clinical remission of atopic
asthma (bottom panel ). Notice the increased tryptase-positive area
(the red stain) and epithelial shedding in the subject in clinical remis-
Figure 5. Thickness of the reticular basement membrane (RBM) (top
panel ) in biopsy specimens from currently asthmatic subjects, subjects
in clinical remission of atopic asthma, and healthy control subjects.
Horizontal bars represent median values. Occupancy of the reticular
basement membrane (RBM) (bottom panel ) with epithelium in biopsy
specimens from currently asthmatic subjects, subjects in clinical remis-
sion of atopic asthma, and healthy control subjects. Results are plotted
as ratio of the length of occupied RBM divided by the total membrane
length. Horizontal bars represent median values.
Figure 6. Eosinophil cell counts in blood samples from currently asth-
matic subjects, subjects in clinical remission of atopic asthma, and
healthy control subjects. Each circle represents one subject. Horizontal
bars represent median values.
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more pronounced than in healthy control subjects. We hy-
pothesize that the severity of airway disease determines the
susceptibility of the epithelium for physical stress. Hence, the
differences we observed between the groups may be a reflec-
tion of the overall integrity of bronchial epithelium in the
asthmatic bronchus compared with the bronchus of subjects in
remission and with that of healthy control subjects.
Exhaled NO levels have already been shown to correlate
with blood and sputum eosinophilia in atopic children and
adults with mild-intermittent asthma (42–44). Our study is the
first to show a significant correlation between eNO levels and
airway eosinophilia, as reflected by MBP density in the airway
mucosa. Recently, eNO levels were reported not to correlate
with mucosal eosinophils (45). This difference may be ex-
plained by methodological factors, which include patient se-
lection and numbers.
Surprisingly, we found enhanced iNOS density in the air-
way wall mucosa from healthy control subjects compared with
asthmatics and subjects in remission. This is not in agreement
with the hypothesis of increased expression of iNOS in airway
epithelium as the cause of elevated eNO (12, 46). We specu-
late that iNOS unrelated mechanisms, including enhanced dif-
fusion of NO through damaged epithelium, or iNOS indepen-
dent NO generation under conditions of airway acidity (47)
may explain this finding in subjects with airways inflamma-
tion. Furthermore, other isoforms of NOS could account for
elevated NO production. After an increase in NO, a negative
feedback mechanism might result in lower iNOS levels in the
airway mucosa from asthmatic subjects.
In conclusion, our study has shown ongoing airway inflam-
mation and airway remodeling in adolescents in clinical remis-
sion of atopic asthma. We speculate that subclinical airway in-
flammation may well determine the risk of asthma relapse
later in life. Furthermore, we hypothesize that subjects with
evidence of airway inflammation during remission could pos-
sibly benefit from anti-inflammatory treatment in the short-
and/or long-term. We propose that blood eosinophils, eNO and
airway responsiveness to AMP, each reflecting distinct parts
of the inflammatory process, may be useful in the long-term
monitoring of asthmatic airway inflammation.
References
1. Panhuysen CI, Vonk JM, Koeter GH, Schouten JP, van Altena R,
Bleecker ER, Postma DS. Adult patients may outgrow their asthma: a
25-year follow-up study. Am J Respir Crit Care Med 1997;155:1267–
1272.
2. Barbee RA, Murphy S. The natural history of asthma. J Allergy Clin Im-
munol 1998;102:S65–72.
3. Kerrebijn KF, Fioole AC, van Bentveld RD. Lung function in asthmatic
children after year or more without symptoms or treatment. Br Med J
1978;1:886–888.
4. Gruber W, Eber E, Steinbrugger B, Modl M, Weinhandl E, Zach MS.
Atopy, lung function and bronchial responsiveness in symptom-free
paediatric asthma patients. Eur Respir J 1997;10:1041–1045.
5. Gillis HL, Lutchen KR. Airway remodeling in asthma amplifies hetero-
geneities in smooth muscle shortening causing hyperresponsiveness. J
Appl Physiol 1999;86:2001–2012.
6. Djukanovic R. Asthma: a disease of inflammation and repair. J Allergy
Clin Immunol 2000;105:522–526.
7. Vignola AM, Chanez P, Bonsignore G, Godard P, Bousquet J. Struc-
tural consequences of airway inflammation in asthma. J Allergy Clin
Immunol 2000;105:514–517.
8. Fahy JV, Corry DB, Boushey HA. Airway inflammation and remodel-
ing in asthma. Curr Opin Pulm Med 2000;6:15–20.
9. Laitinen A, Altraja A, Kampe M, Linden M, Virtanen I, Laitinen LA.
Tenascin is increased in airway basement membrane of asthmatics
and decreased by an inhaled steroid. Am J Respir Crit Care Med 1997;
156:951–958.
10. Hoshino M, Takahashi M, Takai Y, Sim J. Inhaled corticosteroids de-
crease subepithelial collagen deposition by modulation of the balance
between matrix metalloproteinase-9 and tissue inhibitor of metallo-
proteinase-1 expression in asthma. J Allergy Clin Immunol 1999;104:
356–363.
11. Van den Toorn LM, Prins JB, Overbeek SE, Hoogsteden HC, de Jongste
JC. Adolescents in clinical remission of atopic asthma have elevated
exhaled nitric oxide levels and bronchial hyperresponsiveness. Am J
Respir Crit Care Med 2000;162:953–957.
12. Barnes PJ, Liew FY. Nitric oxide and asthmatic inflammation. Immunol
Today 1995;16:128–130.
13. Saleh D, Ernst P, Lim S, Barnes PJ, Giaid A. Increased formation of the
potent oxidant peroxynitrite in the airways of asthmatic patients is as-
sociated with induction of nitric oxide synthase: effect of inhaled glu-
cocorticoid. Faseb J 1998;12:929–937.
14. Robinson DS, Bentley AM, Hartnell A, Kay AB, Durham SR. Acti-
vated memory T helper cells in bronchoalveolar lavage fluid from pa-
tients with atopic asthma: relation to asthma symptoms, lung function,
and bronchial responsiveness. Thorax 1993;48:26–32.
15. Kon OM, Kay AB. T cells and chronic asthma. Int Arch Allergy Immu-
nol 1999;118:133–135.
16. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander
I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P. Eosinophilic
inflammation in asthma. N Engl J Med 1990;323:1033–1039.
17. Moqbel R, Barkans J, Bradley BL, Durham SR, Kay AB. Application of
monoclonal antibodies against major basic protein (BMK-13) and
eosinophil cationic protein (EG1 and EG2) for quantifying eosino-
phils in bronchial biopsies from atopic asthma. Clin Exp Allergy 1992;
22:265–273.
18. Church MK, Levi-Schaffer F. The human mast cell. J Allergy Clin Immu-
nol 1997;99:155–160.
19. Rossi GL, Olivieri D. Does the mast cell still have a key role in asthma?
Chest 1997;112:523–529.
20. Mautino G, Henriquet C, Gougat C, Le Cam A, Dayer JM, Bousquet J,
Capony F. Increased expression of tissue inhibitor of metalloprotein-
ase-1 and loss of correlation with matrix metalloproteinase-9 by mac-
rophages in asthma. Lab Invest 1999;79:39–47.
21. Bousquet J, Corrigan CJ, Venge P. Peripheral blood markers: evaluation
of inflammation in asthma. Eur Respir J Suppl 1998;26:42S–48S.
Figure 7. Correlation between blood eosinophil cell count and Major
Basic Protein (MBP) density in subepithelium (r = 0.45, p = 0.009) (top
panel ) and between exhaled Nitric Oxide (eNO) and MBP density in
the bronchial epithelium (r = 0.40, p = 0.022) (bottom panel) in the
population of subjects in remission and currently asthmatic subjects.
Each dot represents one subject.
Van den Toorn, Overbeek, de Jongste, et al.: Airway Inflammation during Remission of Asthma 2113
22. Crimi E, Spanevello A, Neri M, Ind PW, Rossi GA, Brusasco V. Dissoci-
ation between airway inflammation and airway hyperresponsiveness
in allergic asthma. Am J Respir Crit Care Med 1998;157:4–9.
23. Möller GM, Overbeek SE, van Helden-Meeuwsen CG, Hoogsteden HC,
Bogaard JM. Eosinophils in the bronchial mucosa in relation to meth-
acholine dose-response curves in atopic asthma. J Appl Physiol 1999;
86:1352–1356.
24. Sullivan P, Stephens D, Ansari T, Costello J, Jeffery P. Variation in the
measurements of basement membrane thickness and inflammatory
cell number in bronchial biopsies. Eur Respir J 1998;12:811–815.
25. Jeffery P. Structural alterations and inflammation of bronchi in asthma.
Int J Clin Pract Suppl 1998;96:5–14.
26. Wilson JW, Li X. The measurement of reticular basement membrane
and submucosal collagen in the asthmatic airway. Clin Exp Allergy
1997;27:363–371.
27. American Thoracic Society. Standards for the diagnosis and care of patients
with chronic obstructive pulmonary disease (COPD) and asthma. ATS
statement. Adopted by the ATS Board of Directors, November 1986.
Am Rev Respir Dis 1987;136:225–244.
28. Laitinen LA, Laitinen A, Altraja A, Virtanen I, Kampe M, Simonsson
BG, Karlsson SE, Hakansson L, Venge P, Sillastu H. Bronchial biopsy
findings in intermittent or “early” asthma. J Allergy Clin Immunol
1996;98:S3–6; discussion S33–40.
29. Vignola AM, Chanez P, Campbell AM, Souques F, Lebel B, Enander I,
Bousquet J. Airway inflammation in mild intermittent and in persis-
tent asthma. Am J Respir Crit Care Med 1998;157:403–409.
30. Holgate ST. The immunopharmacology of mild asthma. J Allergy Clin
Immunol 1996;98:S7–16; discussion S33–40.
31. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation
even in patients with newly diagnosed asthma. Am Rev Respir Dis
1993;147:697–704.
32. Bradley BL, Azzawi M, Jacobson M, Assoufi B, Collins JV, Irani AM,
Schwartz LB, Durham SR, Jeffery PK, Kay AB. Eosinophils, T-lym-
phocytes, mast cells, neutrophils, and macrophages in bronchial bi-
opsy specimens from atopic subjects with asthma: comparison with bi-
opsy specimens from atopic subjects without asthma and normal
control subjects and relationship to bronchial hyperresponsiveness. J
Allergy Clin Immunol 1991;88:661–674.
33. Bentley AM, Meng Q, Robinson DS, Hamid Q, Kay AB, Durham
SR. Increases in activated T lymphocytes, eosinophils, and cyto-
kine mRNA expression for interleukin-5 and granulocyte/macro-
phage colony- stimulating factor in bronchial biopsies after aller-
gen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol
Biol 1993;8:35–42.
34. Frew AJ, St-Pierre J, Teran LM, Trefilieff A, Madden J, Peroni D,
Bodey KM, Walls AF, Howarth PH, Carroll MP, Holgate ST. Cellular
and mediator responses twenty-four hours after local endobronchial
allergen challenge of asthmatic airways. J Allergy Clin Immunol 1996;
98:133–143..
35. Gratziou C, Carroll M, Montefort S, Teran L, Howarth PH, Holgate ST.
Inflammatory and T-cell profile of asthmatic airways 6 hours after lo-
cal allergen provocation. Am J Respir Crit Care Med 1996;153:515–520.
36. Koshino T, Arai Y, Miyamoto Y, Sano Y, Itami M, Teshima S, Hirai K,
Takaishi T, Ito K, Morita Y. Airway basophil and mast cell density in
patients with bronchial asthma: relationship to bronchial hyperre-
sponsiveness. J Asthma 1996;33:89–95.
37. Polosa R, Holgate ST. Adenosine bronchoprovocation: a promising
marker of allergic inflammation in asthma? Thorax 1997;52:919–923.
38. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche
WR, Howarth PH, Holgate ST. Quantitation of mast cells and eosino-
phils in the bronchial mucosa of symptomatic atopic asthmatics and
healthy control subjects using immunohistochemistry. Am Rev Respir
Dis 1990;142:863–871.
39. Chetta A, Foresi A, Del Donno M, Consigli GF, Bertorelli G, Pesci A,
Barbee RA, Olivieri D. Bronchial responsiveness to distilled water
and methacholine and its relationship to inflammation and remodel-
ing of the airways in asthma. Am J Respir Crit Care Med 1996;153:
910–917.
40. Perin PV, Weldon D, McGeady SJ. Objective indicators of severity of
asthma. J Allergy Clin Immunol 1994;94:517–522.
41. Ordonez C, Ferrando R, Hyde DM, Wong HH, Fahy JV. Epithelial
desquamation in asthma. Artifact or pathology? Am J Respir Crit
Care Med 2000;162:2324–2329.
42. Horvath I, Donnelly LE, Kiss A, Kharitonov SA, Lim S, Fan Chung K,
Barnes PJ. Combined use of exhaled hydrogen peroxide and nitric ox-
ide in monitoring asthma. Am J Respir Crit Care Med 1998;158:1042–
1046.
43. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation
between exhaled nitric oxide, sputum eosinophils, and methacholine
responsiveness in patients with mild asthma. Thorax 1998;53:91–95.
44. Piacentini GL, Bodini A, Costella S, Vicentini L, Mazzi P, Sperandio
S, Boner AL. Exhaled nitric oxide and sputum eosinophil markers
of inflammation in asthmatic children. Eur Respir J 1999;13:1386–
1390.
45. Lim S, Jatakanon A, Meah S, Oates T, Chung KF, Barnes PJ. Rela-
tionship between exhaled nitric oxide and mucosal eosinophilic in-
flammation in mild to moderately severe asthma. Thorax 2000;
55:184–188.
46. Hamid Q, Springall DR, Riveros-Moreno V, Chanez P, Howarth P,
Redington A, Bousquet J, Godard P, Holgate S, Polak JM. Induction
of nitric oxide synthase in asthma. Lancet 1993;342:1510–1513.
47. Hunt JF, Fang K, Malik R, Snyder A, Malhotra N, Platts-Mills TA, Gas-
ton B. Endogenous airway acidification. Implications for asthma
pathophysiology. Am J Respir Crit Care Med 2000;161:694–699.
